SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a sharp intraday reversal, prompting discussions about potential market manipulation and the strength of the AI sector following Nvidia's earnings; traders are actively debating whether this pullback represents a buying opportunity or the start of a deeper correction, with some pointing to possible Yen carry trade issues.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's stock is trending amid upgrades from analysts, though some community members express concern over valuation relative to competitors and potential interconnect hurdles in the AI sector. Despite strong earnings, the stock experienced a selloff, leading to discussions about a possible short squeeze and whether AI constitutes a bubble.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing heavy volatility, sparking discussions about a potential market correction and whether dip-buying strategies will continue to pay off. Some community members are pointing to broader macroeconomic concerns and the influence of crypto markets, while others are eyeing key support levels for potential reversals. The conversation highlights uncertainty around near-term market direction.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about a potential market bottom and the influence of large institutional players. Community discussions revolve around whether this dip presents a buying opportunity or signals a deeper correction, with some pointing to macro factors and potential liquidations as drivers. Sentiment is mixed, with bullish and bearish arguments clashing amidst the price swings.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to strong Q3 earnings and raised FY26 guidance, sparking bullish sentiment among investors; discussions include the impact of e-commerce growth and a planned move to the Nasdaq. Community members are debating whether Walmart's performance signals broader economic strength or if it's a safe haven during market uncertainty, while also pondering its valuation relative to tech companies.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending downwards, frustrating investors who cite strong deliveries and question the stock's valuation relative to peers. Community members speculate about market manipulation and potential short squeezes while bracing for upcoming earnings. Despite the negative price action, some investors remain optimistic, viewing the current dip as a buying opportunity based on the company's long-term potential.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the price of Bitcoin fluctuates, impacting MicroStrategy's value as a major BTC holder; the community is closely watching key support levels. Discussions revolve around analyst Tom Lee's commentary and potential short squeezes, with some expressing concerns about solvency and potential liquidation. Recent whale activity and overall market sentiment add to the volatility.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders assess its volatile movements amidst optimism in the AI sector. Community discussions revolve around dip-buying strategies and potential profit-taking points, especially with upcoming earnings from key semiconductor players like NVDA. The ongoing government shutdown and concerns about AI valuations add to the uncertainty surrounding this leveraged ETF.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending due to Bitcoin's price volatility, sparking debates on whether to buy the dip or brace for further declines; some community members point to potential manipulation and significant ETF outflows as bearish signals, while others highlight oversold conditions and historical patterns as reasons for optimism, with key options levels around \$50 also in focus.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm...

Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan Capital

Chardan Capital reissued a "buy" rating and set a $20.00 target price on shares of Immuneering in a research report on Thursday...

Immuneering (NASDAQ:IMRX) Announces Quarterly Earnings Results

Immuneering (NASDAQ:IMRX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.03...

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.

Shares of Immuneering Corp. rose 42% in after-hours trading on Wednesday after the company’s Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel showed an 86% overall survival rate in patients with first-line pancreatic cancer at nine months, compared with a 47% benchmark for standard of care.The stock closed Wednesday’s regular session up 7.5% at $9.23.Immuneering said it plans to seek regulatory feedback on its pivotal trial plans in the fourth quarter and, subject to that feedback, aims to launch a Phase 3 trial of atebimetinib plus mGnP by the end of 2025, with patient dosing to begin by mid-2026.&nbsp;The company also expects to initiate additional atebimetinib clinical trial combination arms in 2026, including in non-small cell lung cancer.Progression-free survival at nine months was 53%, compared to a 29% benchmark for standard of care. At six months, overall survival was 94%, and progression-free survival was 70%, both&nbsp;rates exceeding&nbsp;historical benchmarks. Median overall survival has not yet been reached.The treatment was generally well-tolerated. The serious side effects,&nbsp;observed in more than 1 in 10 people, included low white blood cell counts, which can increase the risk of infection, and anemia, characterized by low red blood cell levels. No new safety concerns were identified.CEO Ben Zeskind said the nine-month overall survival data widened the gap against&nbsp;the standard of care, describing the results as “extraordinary.” Chief Scientific Officer Brett Hall said atebimetinib, designed as a Deep Cyclic Inhibitor, represents a “fundamental shift in targeted therapy.”&nbsp;Vincent Chung, principal investigator of the trial at City of Hope, said the results mark “an important step” toward urgently needed new treatment options for pancreatic cancer, adding that the company is also planning a confirmatory study.&nbsp;Separately, Immuneering announced a proposed underwritten public offering of its Class A common stock, or in lieu of stock, pre-funded warrants. The company also stated that Sanofi agreed to purchase $25 million of shares in a concurrent private placement at the public offering price, with both transactions expected to close simultaneously.&nbsp;Immuneering plans to use the proceeds to advance the development of its drug candidates and for general corporate purposes.On Stocktwits, retail sentiment for Immuneering was ‘extremely bullish’ amid a 3,540% surge in 24-hour message volume, placing it among the top 10 trending equities on the platform.&nbsp;One user said the offering “didn’t completely kill the momentum,” adding that it gave them hope for the next trading day.&nbsp;<stembedurl>https://stocktwits.com/Mushichka/message/629894873</stembedurl>Another user said they were in “for the long haul, which now extends into mid-2026,” and added that the stock offering would likely be shrugged off within a day before analysts begin calculating Immuneering’s valuation based on potential sales of what they described as the gold standard for treating pancreatic cancer.<stembedurl>https://stocktwits.com/OptimistJP/message/629894127</stembedurl><a href="https://stocktwits.com/symbol/IMRX">Immuneering’s stock</a> has surged 320% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Immuneering’s stock (IMRX) has surged 320% so far in 2025. (Photo credit: Getty Images)

Why Immuneering Stock Soared Over 40% After-Hours Today

Updated trial data showed its drug atebimetinib nearly doubled survival benchmarks in first-line pancreatic cancer, with the company planning a pivotal Phase 3 study by late 2025.

Equity

Immuneering Stock Rises 21.7% on Supply Agreement With LLY

IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the latter’s investigational cancer drug Olomorasib.Immuneering <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/25/3138395/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Lilly-to-Evaluate-Atebimetinib-in-Combination-with-Olomorasib.html">said</a> that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer (NSCLC) who have progressed on prior therapy.In February, Immuneering announced a similar clinical trial agreement with Regeneron Pharmaceuticals to evaluate Atebimetinib in combination with Libtayo in patients with advanced non-small cell lung cancer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRX">IMRX stock</a> trended within ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. IMRX stock traded 15% higher at the time of writing.<figure class="image"><img style="aspect-ratio:623/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_25_at_12_21_56_PM_png_6149d7e374.webp" alt="IMRX's Sentiment Meter and Message Volume as of 12:25 p.m. ET on Aug. 25, 2025 | Source: Stocktwits" width="623" height="61"><figcaption>IMRX's Sentiment Meter and Message Volume as of 12:25 p.m. ET on Aug. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they will buy more on dips.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/626436428</stembedurl>Another user praised the company saying it has excellent products and good management.<stembedurl>https://stocktwits.com/OptimistJP/message/626406127</stembedurl>Chief Medical Officer of Immuneering Igor Matushansky said that the combination of the company’s drug with Lilly’s has the potential for enhanced tumor regression, delayed emergence of tumor resistance, and prolonged survival relative to monotherapy.&nbsp;&nbsp;&nbsp;&nbsp;“This dual-targeted approach has the potential to improve outcomes in a population with limited effective treatment options,” Matushansky added. Immuneering further said that it will maintain global development and commercialization rights to its drug Atebimetinib.IMRX stock is up by 156% this year and by about 381% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-exec-hints-at-possible-price-hike-on-model-y-in-us/chsssVVRdSR">Tesla Executive Hints At Possible Price Hike On Model Y In US: Retail Highlights Negative Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips

Immuneering said that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer who have progressed on prior therapy.

Shares&nbsp;of Immuneering Corp saw increased retail chatter on Tuesday after the company reported positive interim results from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer.The stock&nbsp;initially surged on the news during morning trade&nbsp;but closed down 23.2% at $1.82 on Tuesday and slipped another 2.2% to $1.78 in after-hours trading.Trading activity likely indicated profit-taking, as Immuneering’s stock has gained more than 25% over the past month.The data demonstrated an overall survival (OS) rate of 94% and a progression-free survival (PFS) rate of 72% at 6 months among 34 patients who received atebimetinib at 320 mg once daily plus modified mGnP.&nbsp;Median OS and PFS had not yet been reached.&nbsp;The benchmark 6-month OS and PFS rates for&nbsp;the current standard-of-care treatment in this population are 67% and 44%, respectively.The overall response rate stood at 39%, with disease control seen in 81% of patients.&nbsp;Investigators noted durable tumor regressions, with multiple lesions reportedly rendered undetectable.&nbsp;No Grade 3 or higher adverse events were observed across most categories typically linked to standard chemotherapy regimens.The data prompted Immuneering to increase the trial’s target enrollment to 50 patients.&nbsp;A pivotal, randomized trial is planned for 2026, pending regulatory feedback later this year.Immuneering said additional Phase 2a data and regulatory milestones are expected in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user noted that the stock has never undergone a reverse split and suggested it has multiple upside targets, even speculating on potential buyout interest.&nbsp;<stembedurl>https://stocktwits.com/sam92/message/618211510</stembedurl>Another long-time holder said belief in the stock remains strong.<stembedurl>https://stocktwits.com/Starkravingmad/message/618210680</stembedurl>The stock has declined 17.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally

The company plans to launch a pivotal trial in 2026 and expects additional clinical data and regulatory feedback by the end of 2025. 

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.31	--	--	N/A
Q3 '25	-$0.39	-$0.38	2.15%	BEAT
Q2 '25	-$0.40	-$0.40	0.07%	BEAT
Q1 '25	-$0.53	-$0.42	20.25%	BEAT
Q4 '24	-$0.42	-$0.58	-39.42%	MISSED

IMRX
Immuneering Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest IMRX News

IMRXImmuneering Corp